FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody or its functional fragment that specifically binds to the human programmed cell death ligand 1 (PD-L1), as well as to the composition containing it. A method for inhibiting the proliferation of cancer cells in a subject is also disclosed, including the introduction of the above antibody or its functional fragment to a cancer-bearing subject.
EFFECT: invention makes it possible to effectively treat cancer in the subject.
28 cl, 6 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-INTERFERON BETA ANTIBODIES AND THEIR USE | 2017 |
|
RU2750454C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
